Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: A retrospective study

BMC Cancer

Volumn 9, Issue , 2009, Pages 347-

  Lièvre, Astrid ^a,b   Samalin, Emmanuelle ^c   Mitry, Emmanuel ^a,b   Assenat, Eric ^c   Boyer Gestin, Christine ^c   Lepère, Céline ^a   Bachet, Jean Baptiste ^a   Portales, Fabienne ^c   Vaillant, Jean Nicolas ^a   Ychou, Marc ^c   Rougier, Philippe ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON PERFORATION; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPISTAXIS; FEMALE; GRAND MAL SEIZURE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 70449358710     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-347     Document Type: Article

References (34)

1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30. 10.1200/JCO.2004.09.046, 14665611.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914. 10.1056/NEJM200009283431302, 11006366.
5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77(7):527-543. 10.1007/s001099900019, 10494799.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21(1):60-65. 10.1200/JCO.2003.10.066, 12506171.
8. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23(16):3697-3705. 10.1200/JCO.2005.05.112, 15738537.
9. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
10. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-1544. 10.1200/JCO.2006.09.6305, 17442997.
11. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006, 24(21):3354-3360. 10.1200/JCO.2005.05.1573, 16849749.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
13. Common Toxicity Criteria (CTC) v2.0. , http://cancer.gov/
14. El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 2008, 255(2):295-296. 10.1007/s00415-008-0692-2, 18283405.
15. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005, 93(5):510-514. 10.1038/sj.bjc.6602733, 2361607, 16091760.
16. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005, 56(1):10-14. 10.1007/s00280-004-0963-2, 15782313.
17. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004, 91(5):839-843. 2409883, 15266319.
18. Rimassa L, Gullo G, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T, Santoro A. Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori 2006, 92(4):285-289.
19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345. 10.1056/NEJMoa033025, 15269313.
20. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048. 10.1056/NEJMoa071834, 18003960.
21. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664. 10.1200/JCO.2006.08.1620, 17470858.
22. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
23. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67(6):2643-2648. 10.1158/0008-5472.CAN-06-4158, 17363584.
24. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19(3):508-515. 10.1093/annonc/mdm496, 17998284.
25. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96(8):1166-1169. 10.1038/sj.bjc.6603685, 2360149, 17375050.
26. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379. 10.1200/JCO.2007.12.5906, 18202412.
27. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427(6976):695. 10.1038/427695a, 14973470.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62. 10.1126/science.1104819, 15637262.
29. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2):145-147. 10.1038/nm988, 2693485, 14745444.
30. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(5):672-680. 10.1200/JCO.2008.19.8135, 19114685.
31. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(6):563-572. 10.1056/NEJMoa0808268, 19196673.
32. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23(16):3706-3712. 10.1200/JCO.2005.00.232, 15867200.
33. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-4786. 10.1200/JCO.2007.11.3357, 17947725.
34. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007, 13(46):6231-6235. 10.3748/wjg.13.6231, 18069765.